MedPath

Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis

Conditions
Multiple Sclerosis
MS, Multiple Sclerosis
Registration Number
LBCTR2020030215
Lead Sponsor
Merck KGaA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
8
Inclusion Criteria

1. Patients with MS randomised in CLARITY/CLARITY-EXT clinical trial(s) who have received = 1 course of IMP (Cladribine Tablets or placebo).
or
Patients with their FCDE randomised in ORACLE MS clinical trial who have received= 1 course of IMP (Cladribine Tablets or placebo).
2. Informed Consent

Exclusion Criteria

1. Medical Conditions:
Any condition, including any uncontrolled disease state other than MS, that in the Investigator’s opinion, constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or
evaluation.

For the MRI sub-study:
1. Female Participants Who are pregnant
2. Patient taking Cladribine Tablets as part of another study at the time of the start of this study

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ame: To evaluate long-term mobility after treatment with an investigational medicinal product (IMP; Cladribine Tablets or placebo) as part of the Phase III ORACLE MS and CLARITY/CLARITY-EXT clinical trials.;Timepoints: Proportion of study participants using a wheelchair (defined as unable to walk beyond approximately 5 meters even with aid, essentially restricted to wheelchair; wheels self in standard wheelchair and transfers alone; up and about in wheelchair some 12 hours a day) the majority of the time in the 3 months prior to Study Visit 1 for the CLARITY/CLARITY-EXT and ORACLE MS populations,;Measure: • Expanded Disability Status Scale (EDSS) score of 7.0 or higher (if available), or • Alternative clinical description data in medical records.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath